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CancerAs part of an ongoing study of L-lactate metabolism both in normal and in cancer cells, we investigated
whether and how L-lactate metabolism occurs in mitochondria of human hepatocellular carcinoma (Hep
G2) cells. We found that Hep G2 cell mitochondria (Hep G2-M) possess an L-lactate dehydrogenase (mL-
LDH) restricted to the inner mitochondrial compartments as shown by immunological analysis, confocal mi-
croscopy and by assaying mL-LDH activity in solubilized mitochondria. Cytosolic and mitochondrial L-LDHs
were found to differ from one another in their saturation kinetics. Having shown that L-lactate itself can
enter Hep G2 cells, we found that Hep G2-M swell in ammonium L-lactate, but not in ammonium pyruvate
solutions, in a manner inhibited by mersalyl, this showing the occurrence of a carrier-mediated L-lactate
transport in these mitochondria. Occurrence of the L-lactate/pyruvate shuttle and the appearance outside mi-
tochondria of oxaloacetate, malate and citrate arising from L-lactate uptake and metabolism together with
the low oxygen consumption and membrane potential generation are in favor of an anaplerotic role for L-
LAC in Hep G2-M.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
In mammalian cells, energy metabolism of L-lactate (L-LAC) was
mostly reported as limited to L-LAC oxidation to pyruvate (PYR) in
the cytosol with further PYR metabolism in mitochondria [see Ref.
[1]]. However, it has been shown conclusively that mitochondria can
participate in L-LAC metabolism by virtue of a mitochondrial L-LDH
(mL-LDH) shown to exist in a variety of mammalian mitochondria [see
Refs. [2,3]] and included in over 1000proteins that comprise themamma-
lian mitochondrial proteome reported in the MitoCarta [http://www.
broadinstitute.org/pubs/MitoCarta/index.html]. Furthermore, the exis-
tence of a putative L-lactate oxidase in rat liver mitochondria has also
been reported [4].
L-LAC metabolism is of special interest in cancer cells where an
enhanced production of L-LAC with respect to normal cells occurs,
due to the increased glycolytic ﬂux in aerobic conditions (Warburg+39 0874418295.
rights reserved.effect). Even though a detailed research into L-LAC metabolism of
cancer cells could lead to future signiﬁcant advances in understanding
and dealing with cancer, it has been a largely ignored or misunderstood
area of cancer research. In particular, in cancer cells L-LAC is still con-
sidered by some authors as a waste product of metabolism [5–11]
that is removed from the cell by a family of monocarboxylate trans-
porters [see Ref. [12]]. On the other hand in solid tumors L-LAC was
shown tomigrate from hypoxic to oxygenated tumor cell subpopula-
tions to support oxidative metabolism [13]. In this regard, L-LAC was
recently proposed as a major energy fuel in tumors resulting from its
cytosolic oxidation to PYR and later PYR oxidation in the mitochon-
dria [14].
Demonstration of the occurrence of a mL-LDH has required a
substantial revision of views on L-LAC metabolism in cancer cells. This
revision has already started since it was shown that both normal
(PNT-1A) and cancer (PC-3) prostate cells can take up L-LAC and,
more importantly, show an active mitochondrial metabolism for L-LAC
arising from the occurrence of a mL-LDH, whose expression and activity
were enhanced in PC-3 cells [15]. Similarly, the occurrence of both
monocarboxylate (including L-LAC) transporters (MCT) and mL-LDH
was shown in breast cancer cell lineswithMCT and L-LDH isoforms hav-
ing distinct expression patterns in two cell lines potentially contributing
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In particular, because of the variability of cancer types, it is essential to
obtain further evidence that L-LAC metabolism can occur in mitochon-
dria of other cancer cells and to elucidate the role of L-LAC metabolism
in the mitochondria of these cells. To gain further insight into this
issue we have used human hepatocellular carcinoma (Hep G2) cells.
Hep G2 cells are differentiated cells that display morphological and
functional features of normal hepatocytes [17,18] in which oxidative
metabolism was proposed to occur to respond to energy requirements
[19]. Moreover, mitochondria isolated from liver homogenate,
which exhibit a close similarity with those from isolated hepatocytes
[20], could be used as a heterologous control and be compared to Hep
G2 cell mitochondria (Hep G2-M). It should be noted that the mito-
chondrial bioenergetic proﬁle has recently been investigated in
Hep G2 cells [21]. On the other hand, since Hep G2 cells are highly re-
sistant to chemotherapy [22], they might represent a good model for
the discovery of potential anticancer agents that act by targeting cell
metabolism and mitochondrial function with emerging opportuni-
ties in the therapy of both cancer and other diseases [see Ref. [23]].
In this regard, inhibition of glycolysis by blocking L-LDH was
suggested to be useful in the treatment of human hepatocellular car-
cinomas [24], even if in other cells it has been shown that when gly-
colysis is totally abolished, tumor growth is not signiﬁcantly affected
[25].
Here we show that also Hep G2 cells possess their own mL-LDH
located in the inner compartments and that Hep G2 cells can take up ex-
ternally added L-LAC. ThemL-LDH,which appears to differ from the cyto-
solic isoform, allows for NAD+-dependent L-LAC oxidation resulting in
low oxygen consumption and membrane potential generation. More
importantly, the reconstruction of the L-LAC/PYR shuttle has been
performed, which allows for the oxidation of NADH generated out-
side Hep G2-M. Since the mitochondrial metabolism of L-LAC results
in synthesis and export of oxaloacetate (OAA), malate and citrate
into the extramitochondrial phase, we propose an anaplerotic role
for the mitochondrial L-LAC metabolism.2. Material and methods
2.1. Materials
Arsenite, ATP, bovine serum albumin, ATP-dependent citrate lyase
(CL) (EC 4.1.3.6), Coenzyme A, cysteine, dithiothreitol, Na-EDTA,
EGTA, FCCP, glucose, glucose-6-phosphate, HEPES, potassium hydrox-
ide, L-glutamic acid, L-glutamine, L-lactic acid, bovine heart L-LAC
dehydrogenase (L-LDH) (EC 1.1.1.27), leupeptin, malic acid, chicken
liver malic enzyme (ME) (EC 1.1.1.40), porcine heart malate dehydroge-
nase (MDH) (EC 1.1.1.37), NAD+, oxamate, penicillin/streptomycin,
pepstatin, phenylmethanesulfonyl ﬂuoride, phosphate-buffered saline
(PBS), potassium cyanide, rotenone, succinic acid, Tris, Triton X-100 and
Tween-20, mersalyl, pyruvic acid and NADH, (the last three as well as
others, where indicated by the producers, being freshly prepared)
were from Sigma-Aldrich Chemie (Steinheim, Germany); skimmed
milk powder and ouabain were from Fluka (Mallinckrodt, Buchs,
Switzerland). Sucrose was from Baker (Deventer, The Netherlands).
All chemicals were of the purest grade available and were used as Tris
salts at pHs 7.0–7.4. Rotenone and FCCP were dissolved in ethanol.
Fetal bovine serum and RPMI-1640 were from BioSpa (Milan, Italy).
Both primary goat polyclonal anti-LDH, goat polyclonal anti-
β-actin, rabbit polyclonal anti-COX IV and secondary anti-goat and
anti-rabbit horseradish peroxidase conjugated sera were from
Abcam Plc. (Cambridge, UK). Monoclonal anti-LDHwas from Novus bi-
ologicals, cat. NBP1-47822 and Golgb1 was from Sigma Life Sciences, cat.
HPA011008. AlexaFluor-546, AlexaFluor-488 secondary antibodies and
MitoTracker Red (M7513) were from Invitrogen. DAPI dihydrochloride
was from Calbiochem.2.2. Cell cultures
Hep G2 cells were obtained from the European Collection of Cell
Cultures (ECACC Salisbury, UK). Hep G2 cells were maintained at
37 °C in the presence of 5% CO2 in RPMI-1640 supplemented with
10% inactivated fetal bovine serum, 2 mM glutamine, 100 U/ml of
penicillin and 100 μg/ml of streptomycin.
2.3. Cell suspension, cell homogenate, mitochondria and cytosolic fraction
preparation
Before each experiment, the culture medium was removed and
the plated Hep G2 cells were washed with PBS medium containing
138 mM NaCl, 2.7 mM KCl, 8 mM Na2HPO4, 15 mM KH2PO4, pH 7.4,
and then collected by gentle scraping into a 1 ml of PBS medium.
Cell suspension was obtained by centrifuging collected cells at
800×g for 2 min and suspending the pellet in the same volume of
PBS medium (pH 7.4). Cell membrane integrity was assayed by try-
pan blue exclusion assay [26].
The ﬁnal cell suspension routinely contained 85–95% intact cells.
Cell homogenates from a cell suspension were obtained by 30 gentle
strokes with a Dounce Potter homogenizer at room temperature.
Rupture of cell membranes was assayed by trypan blue exclusion
assay [26]. Mitochondriawere isolated essentially as in Ref. [27]. Brieﬂy,
cells (about 200×106, grown to 80% conﬂuence) were washed three
times with PBS, scraped from the dishes and suspended in 14 ml cold
isolation buffer (0.32 M sucrose, 1 mM EDTA, 10 mM Tris–HCl, pH
7.4). Cells were homogenized at 4 °C by 4 strokes (A — pestle) and
8 strokes (B— pestle)with a Dounce homogenizer and then centrifuged
at 1330×g for 10 min. The supernatant was carefully decanted; the
pellet was suspended in 7 ml of isolation buffer using a Dounce homog-
enizer, centrifuged at 1330×g for 5 min, and the supernatant retained.
The combined supernatants were centrifuged at 21,200×g for 10 min.
3–4 mg mitochondrial protein was obtained. If more highly puriﬁed
mitochondria were required the pellet was re-suspended in 15% Percoll
solution, carefully layered onto a discontinuous Percoll gradient (23%
over 40%) and centrifuged at 30,700×g for 15 min (Percoll solution was
prepared in isolation buffer and concentration is reported as % (v/v)).
The band at the interface between the 23% and 40% Percoll layers was
collected, diluted 1:4 in isolation buffer and then centrifuged at
16,700×g for 10 min. The pellet was suspended in the same volume of
fresh isolation buffer and centrifuged again at 6900×g for 10min. About
0.5 mg mitochondrial protein was obtained. Mitochondria isolated from
cells or present in cell homogenates were suspended in PBS and checked
for their intactness in each experiment bymeasuring the activities of ADK
(E.C.2.7.4.3) and GDH (E.C.1.4.1.3) [see Ref. [28]] which are marker
enzymes of the mitochondrial intermembrane space and matrix, respec-
tively. In a parallel experiment in which either Hep G2-M or rabbit
gastrocnemius mitochondria were isolated in the presence of protease,
in distinction with the results reported below and in Ref. [29], we
obtained a lower yield of mitochondria which proved to be almost
uncoupled with a signiﬁcant release of the above marker enzymes.
Cytosolic fractions were obtained by centrifuging (105,000×g for
60 min) the supernatant obtained during isolation of mitochondria.
Glucose-6-phosphate dehydrogenase (E.C. 1.1.1.49), a cytosolic marker,
was assayed as described [30] in both the mitochondrial and cytosolic
fractions. All the operations were made on ice and the centrifugations
at 4 °C. Mitochondrial and cytosolic protein content was determined
by the Bradford method [31] with bovine serum albumin (BSA) used
as a standard.
2.4. Immunoblot analysis
Immunoblot analysis was performed on either mitochondrial or
cytosolic proteins by using antibodies against LDH, COX-IV and β-actin.
Antibodies recognizing COX-IV and β-actin were used as markers of
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or cytosolic or cell total fractions were added to a medium con-
sisting of 500 mM NaCl, 50 mM Tris/HCl (pH 7.5), 1 mM EGTA,
1 mM Na-EDTA, 0.5 mM dithiothreitol, 2 mM phenylmethanesulfonyl
ﬂuoride, 10 μg/ml aprotinin, 10 μg/ml leupeptin, and 10 μg/ml pepstatin
in the presence of 1% Triton X-100, used to solubilize mitochondria as
well as any cell vesicles formed in the isolation ofmitochondria. Protein
content was determined using the Bradford reagent (Bio-Rad Laborato-
ries, Hercules, CA, USA), with BSA as a standard. Solubilized proteins
(20 μg) were subjected to electrophoresis on 12% SDS/polyacrylamide
gels [32]. Following electrophoresis, protein blots were transferred to
a poly-(vinylidenediﬂuoride) membrane. The membrane was blocked
with 5% non-fat milk in Tris buffer solution (pH 7.5), and incubated
overnight with the corresponding primary antibodies at 4 °C. After
washing three times with Tris buffer solution (pH 7.5) plus Tween-20
(0.3%), the membrane was incubated at room temperature for 1 h
with horseradish peroxidase-conjugated secondary antibody. The
detected protein signals were visualized with enhanced chemilumines-
cence Western blot reagents (Amersham, ECL, Little Chalfont, UK).
2.5. Confocal microscopy
Hep G2 cells were seeded at 25% conﬂuence in IBIDI 6 well cham-
bers (Ibidi GmbH) in RPMI-1640 supplemented with 10% inactivated
fetal bovine serum, 2 mM glutamine, at 37 °C and 5% CO2 (“growth
conditions”). After 36 h, cells were ﬁxed for 2 min in freshly prepared
acetone/methanol 1:1 mixture at room temperature. After washing
with PBS and blocking by treatment with 1% BSA in PBS for 10 min,
cells were co-immunostained for L-LDH with the monoclonal antibody
for L-LDH and COX-IV, or Golgb1, 1:100 diluted in PBS containing 1%
BSA and incubated at room temperature for 30 min. Secondary anti-
bodies for L-LDH, COX-IV and Golgb1 were incubated at 1:200 dilution
in PBS containing 1% BSA for 15 min at room temperature. To label
mitochondria the cells were incubated with MitoTracker Red (50 nM)
for 15 min at 37 °C and then processed for immunoﬂuorescence. A
construct containing cytosolic GFP-PAH (GFP-phenylalanine hydroxy-
lase) fusion protein [33] was transiently transfected in Hep G2 cells
and its localization was analyzed by confocal microscopy after ﬁxation
with methanol/acetone (1:1).
Nuclei were stained with 1 μg/ml DAPI in PBS for 5 min, at room
temperature. Slides were mounted with 50% glycerol in PBS and im-
aged using a Zeiss LSM 510 meta confocal microscope equipped
with an oil immersion plan Apochromat 63× objective 1.4 NA, using
the following settings: green channel for detecting Alexa488, excita-
tion 488 nm argon laser, emission bandpass ﬁlter 505–550 nm; red
channel for detecting Alexa546, excitation 543 nm Helium/Neon
laser, emission bandpass ﬁlter 560–700 nm (by using the meta mono-
chromator); blue channel for detecting DAPI, excitation 405 nm blue
diode laser, and emission bandpass 420–480 nm.
Co-localizationswere quantiﬁed by calculating the Pearson coefﬁcient
[34] in regions of L-LDH and COX-IV or Golgb1 co-presence. In brief, the
Otsu algorithm was applied to segment COX-IV and Golgb1 images [35],
in order to deﬁne co-localization regions of the twomarkers. The Pearson
coefﬁcient was then calculated in the deﬁned regions for the two images
of interest, namely L-LDH/COX-IV and L-LDH/Golgb1. The two steps were
performed using Matlab software (The Mathworks, Inc.). 3D reconstruc-
tion of 1 μm interval Z slices was performed by using LSM 510 software.
2.6. Enzymatic assays
Assay of L-LDH was performed photometrically at 25 °C by means
of a Jasco (Tokyo, Japan) V570 spectrophotometer at a wavelength of
334 nm, as in Ref. [36], by following as a function of time the absor-
bance changes reﬂecting either NADH oxidation or NAD+ reduction
resulting from PYR or L-LAC addition, respectively. For the assays,
either cytosolic fractions or Triton X-100 solubilized puriﬁed HepG2-M (0.01 mg of protein), were incubated in 2 ml of standardmedium
with 0.2 mMNADH, or 1 mMNAD+ in the presence of rotenone (2 μg)
to avoid NADH oxidation by complex I in the case of Hep G2-M, and the
appropriate substrate was then added to start the reaction. Rates were
obtained as the tangent to the initial part of the progress curves and
expressed as nmol of NADH-oxidized/NAD+-reduced×min−1×mg−1
protein (A334 nm=6.22 mM−1×cm−1).
2.7. Fluorimetric assays of the redox state of pyridine nucleotides
Changes in the redox state of pyridine nucleotides were monitored
ﬂuorimetrically, using a Perkin-Elmer (Beaconsﬁeld, UK) LS50B spec-
troﬂuorimeter set at excitation and emission wavelengths equal to
334 and 456 nm, respectively. Uptake of L-LAC was monitored as de-
scribed in Ref. [15]. Hep G2 cells were incubated in 2 ml of PBSmedium
in the presence of FCCP (1 μM) followed by addition of rotenone (2 μg).
NAD(P)+ reduction due to L-LAC addition was observed as an increase
in ﬂuorescence, and the rate of reaction was calculated as the tangent to
the initial part of the progress curve and expressed as nmol NAD(P)+
reduced×min−1×mg−1 protein.
The NAD(P)H ﬂuorescence was calibrated as described [36].
2.8. Swelling experiments
Mitochondrial swelling was monitored photometrically at a wave-
length of 546 nm as in Ref. [37]. Hep G2-M (0.1 mg protein each)
were rapidly added to isotonic solutions of ammonium salts the pH
values of which were adjusted to 7.4, and the decrease in absorbance
was recorded.
2.9. Polarographic measurements
Oxygen consumption was measured polarographically using a
Hansatech oxygraphwith a Clark electrode. Hep G2-M (0.5 mg protein)
were incubated in a thermostated (25 °C) water-jacketed glass vessel
containing PBS (ﬁnal volume 1 ml) medium. Since the incubation
chamber required continuous stirring to allow oxygen to diffuse freely,
the design included amagnetic stirring system. The rate of oxygen uptake
wasmeasured with the appropriate software from the tangent to the ini-
tial part of the progress curve and expressed as nmol O2×min−1×mg−1
protein. The sensitivity of the instrument was set so as to allow rates of
oxygen consumption as low as 0.1 nmol O2 min−1×mg−1 protein to be
measured.
2.10. Assay of the safranine response
Tomonitor themitochondrial membrane potential use wasmade of
safranine O as a ﬂuorescence probe, (λex=520 nm, λem=570 nm), as
described in Ref. [38]. Measurements were carried out at 25 °C in 2 ml
of PBS containing safranine O (10 nmol/mg mitochondrial protein).
2.11. Other photometric measurements
Appearance of PYR, OAA and citrate outsidemitochondria wasmon-
itored by using the pyruvate detecting system (P.D.S.) consisting of
0.2 mM NADH plus L-LDH (1 e.u.), the OAA detecting system (O.D.S.)
consisting of 0.2 mM NADH plus malate dehydrogenase (1 e.u.) and
the citrate detecting system (C.D.S.) consisting of O.D.S. plus citrate
lyase (1 e.u.), ATP (1 mM) and coenzyme A (1 mM). The rate of appear-
ance of citratewas calculated by subtracting the rate of OAA appearance
from the rate of absorbance decrease found in the presence of the C.D.S.
Appearance of malate was monitored photometrically by follow-
ing the absorbance increase at a wavelength of 334 nm in the pres-
ence of the malate detecting system (M.D.S.) consisting of 200 μM
NADP+ plus malic enzyme (ME 0.2 e.u.). The value of ε334 measured
Fig. 1. Immunodetection of mitochondrial L-LDH.Solubilized protein (20 μg) from total
cell, cytosolic and mitochondrial fractions was analyzed by Western blotting as
described in Section 2.4. Membrane blots were incubated with polyclonal anti-L-LDH,
anti-COX-IV and anti- β-actin. COX-IV and β-actin were used as mitochondrial and
cytosolic markers, respectively.
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6.22 mM−1×cm−1.
L-LAC itself proved to have no effect on the enzymatic reactions or
on absorbance measurements. Moreover, controls were carried out to
ensure that none of the compounds used affected the enzymes used
to reveal appearance of metabolites outside mitochondria.
2.12. Statistical analysis and computing
Data are reported as themean±standard deviation (S.D.). Statistical
analysis was performed using Student's t test. Experimental plots were
obtained using Graﬁt software (Erithacus).
3. Results
3.1. The occurrence of L-lactate dehydrogenase in Hep G2 cell mitochondria
Mitochondrial metabolism of L-LAC requires that HepG2-Mpossess
their own mL-LDH. To show this we resorted to three different
procedures: immunological analysis, confocalmicroscopy and enzymat-
ic assay.
Western blot analysis was carried out by using goat polyclonal
antibodies raised against L-LDH, which have already been shown to
cross-react with L-LDH from different species [15,36,38,39]. Solubi-
lized proteins (20 μg) from total cell protein extracts, cytosolic frac-
tion and puriﬁed mitochondria were analyzed by SDS PAGE, blotted
onto poly(vinylidene diﬂuoride) membrane, and then probed with
the antibody to L-LDH (Fig. 1). L-LDH protein was visualized as a
single band in all three of the fractions.
In order to exclude cross-contamination between cytosolic and
mitochondrial fractions, β-actin and subunit IV of the cytochrome c
oxidase (COX-IV) were used as speciﬁc markers of cytosol and mito-
chondria, respectively. Use of a speciﬁc antibody against subunit IV of
COX revealed a single band in both mitochondrial and total extract,
but not in the cytosolic fraction, showing that minimal rupture of
Hep G2-M had occurred during isolation. Moreover, by using an
antibody speciﬁc for β-actin, it was shown that the mitochondrial
fraction did not contain β-actin, thus ruling out that the detected
mL-LDH arose from cytosolic contamination.
To conﬁrm the localization of L-LDH in Hep G2-M, we co-
immunostained Hep G2 cells with the antibody speciﬁc for either
L-LDH or COX-IV (Fig. 2a). L-LDH was found not only in the cytosol
(as expected) but, in agreement with previous reports of results using
other cell lines [40,41], also in the mitochondria where L-LDH and
COX co-localized. These data were strengthened by ﬁnding of co-
localization of LDH with the mitochondrial dye MitoTracker Red
(Fig. 2b). In order to check the signiﬁcance of co-localization, the Pearson
Correlation coefﬁcient (PC) [34] was used to test areas of the images
corresponding to mitochondria and L-LDH. A PC average value higher
than 0.6 (N=100) was found, which conﬁrmed that in Hep G2 cells,
L-LDH is localized in mitochondria. As a negative control, L-LDH co-
immunostaining was performed also with the antibody speciﬁc for
giantin (Golgb1), a marker of the Golgi apparatus (Fig. 2c). As expected,
the PC test produced a value close to zero, which conﬁrmed the absence
of L-LDH in the Golgi apparatus. To rule out that non-speciﬁc labeling
could occur we conﬁrmed that no mitochondrial co-localization occurs
for GFP-PAH (Fig. 2d) which is a cytosolic protein [33].
3.2. Localization of L-lactate dehydrogenase in Hep G2 cell mitochondria
Having shown the existence of an mL-LDH, experiments were carried
out to determine in which mitochondrial compartments it is localized.
The activity of the enzyme was measured by monitoring the decrease/
increase of absorbance for NADH plus PYR or NAD+ plus L-LAC used
as substrate pairs respectively, either in intact or in solubilized puriﬁed
mitochondria (Fig. 3). In the former case (trace a), the NADH absorbancewas constant this showing that Hep G2-M were intact; no signiﬁcant
change of NADH/NAD+ absorbance was found as a result of addition of
either PYR (0.1 mM) or L-LAC (1 mM) (not shown) to intact Hep
G2-M, this conﬁrming the absence of any cytosolic L-LDH contamination
and showing the absence of the mL-LDH in the outer membrane, in the
intermembrane space and on the outer side of the mitochondrial inner
membrane. As a result of addition of Triton X-100 (0.1%), after a fast
absorbance decrease due to Hep G2-M solubilization, NADH oxidation
was found at a rate of about 700 nmol NADH oxidized×min−1×mg−1
of mitochondrial protein. The addition of oxamate (5 mM), an L-LDH in-
hibitor [42], decreased the oxidation rate to about 90 nmol NADH
oxidized×min−1×mg−1 of mitochondrial protein. In Triton X-100-
treated Hep G2-M, which themselves oxidize NADH at a rate of about
70 nmol×min−1×mg−1, probably due to residual complex I activity,
addition of PYR (0.1 mM) resulted in a rate of 700 nmol NADH
oxidized×min−1×mg−1 (trace b). In parallel, the mitochondrial L-LDH
reaction was monitored as NADH formation resulting from addition of
L-LAC to Triton X-100-treated Hep G2-M in the absence of any PYR trap-
ping system (trace c). In this case the measured rate of NAD+ reduction
was about 240 nmol NAD+ reduced×min−1×mg−1. No G6PDH activity
was found either in intact or solubilizedHepG2-M. The former assay pro-
vided further conﬁrmation of lack of cytosolic contamination while the
latter assay ruled out the possibility that mitochondria were contaminat-
ed by plasma membrane vesicle which could release cytosolic enzymes,
including L-LDH, on Triton X-100 treatment (not shown).
The dependence of the rate of either absorbance decrease (NADH
oxidation) or increase (NAD+ reduction) on increasing concentra-
tions of either PYR/NADH or L-LAC/NAD+ externally added to either
solubilized Hep G2-M or to cytosolic fractions was investigated
(Fig. 4). In both cases saturation kinetics were found. The Km values
for PYR, L-LAC and NAD+ measured in the solubilized Hep G2-M
were found to differ from those measured in the cytosolic fractions.
3.3. L-Lactate can enter Hep G2 cells and Hep G2 cell mitochondria
In addition to metabolism of L-LAC generated from glycolysis, the
mitochondrial L-LDH might also be involved in metabolism of L-LAC
from external sources (such as blood L-LAC in vivo). To investigate
this possibility we ﬁrst determined whether externally added L-LAC
can enter Hep G2 cells. This was done as in Ref. [15] by monitoring
ﬂuorimetrically the redox state of the intracellular pyridine nucleo-
tides (Fig. 5a). The effects of both glucose and PYR were tested in
the same experiment. In a typical experiment, Hep G2 cells were
treated with the uncoupler FCCP (1 μM) which caused the oxidation
of the intramitochondrial NAD(P)H. When the ﬂuorescence remained
Fig. 2. Confocal micrographs of Hep G2 cells showing localization of LDH in the mitochondria.(a) Hep G2 cells were co-immunostained with L-LDH antibody and COX-IV, an
antibody speciﬁc for a mitochondrial cytochrome oxidase subunit. L-LDH (green) localized in the mitochondria (red), as showed by the yellow-orange regions of overlay image.
High magniﬁcation inset is shown on the right panel a.(b) Cells were ﬁrst incubated with MitoTracker Red and processed for immunoﬂuorescence with anti-LDH antibody. LDH
(green) localized in the mitochondria (red). High magniﬁcation inset is shown on the right panel b.(c) Cells were co-immunostained with the L-LDH antibody and a marker of
the Golgi apparatus Golgb1. L-LDH (green) did not localize in the Golgi apparatus (red), as showed by the overlay image in which red regions retain their color, indicating no
co-localization with Golgb1. 3D reconstruction of 15 Z slices 1 μm interval is shown on the right panel c.(d) Hep G2 cells transiently transfected with GFP-PAH were immunostained
with anti-COX-IV (red) to label mitochondria.The experiments were repeated 3 times and analogous results were obtained from at least 100 cells for each experiment. Size bars:
10 μm.
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themitochondrial oxidation of the NAD(P)H newly formed in themito-
chondrial matrix from externally added substrates. As a result of addi-
tion of rotenone, a large increase in NAD(P)H ﬂuorescence was found
presumably arising from the oxidation of endogenous substrates via
NAD+-linked reactions. When the ﬂuorescence was constant, L-LAC
(5 mM) and PYR (1 mM)were added separately. As a result of the addi-
tion of L-LAC, but not of PYR, an increase in ﬂuorescence occurred at a
rate of about 0.6 nmol NAD(P)+ reduced×min−1×mg−1 cell protein
showing that L-LAC can enter Hep G2 cells. The L-LAC-dependent
increase of ﬂuorescence was mostly insensitive to arsenite (1 mM),
which can enter the cell and can inhibit the pyruvate dehydrogenase
complex [see Ref. [15]] thus ruling out the involvement of this
complex in NAD(P)H generation (not shown). As PYR addition had
no effect on the NAD(P)H ﬂuorescence, we conclude that the ﬂuores-
cence increase is essentially due to L-LAC uptake by the cell with sub-
sequent intramitochondrial oxidation of L-LAC via the mL-LDH.
Addition of glucose (10 mM) to the Hep G2 cells also led to an
increase in ﬂuorescence (inset of Fig. 5a) but this was completely
blocked by the subsequent addition of ouabain, which prevents glucose
uptake by inhibiting the Na+/K+ ATPase [43]. This shows that the cells
were intact and are compatible with formation of L-LAC in glycolysis,
and its ﬁnal oxidation inside mitochondria.Thus for initial investigations of themechanism bywhich Hep G2-M
can take up externally added L-LAC we used mitochondrial swelling in
ammonium L-LAC solution (0.1 M) as monitored by absorbance
decrease at 546 nm (Fig. 5b). Swelling in an isotonic solution of the
ammonium salt of a penetrant anion is characteristic of mitochondria
[44]. The decrease of absorbance of the Hep G2-M suspension in NH4-
L-LAC (Fig. 5b trace f) shows that they can take up L-LAC and that this
occurs in a proton-compensated manner. Both the rate and the ampli-
tude of swelling were higher than that which occurred in ammonium
phosphate (Fig. 5b trace d), which enters mitochondria via its own
carrier [see Ref. [29]]. No signiﬁcant swelling was found in 0.25 M
sucrose (Fig. 5b trace a), showing the intactness of the mitochondrial
membranes. Interestingly, as expected from the results in Fig. 5a and
in agreement with Ref. [45], poor swelling of Hep G2-M in ammonium
PYR was found (Fig. 5b trace c). In order to ﬁnd out whether L-LAC can
enter Hep G2-M in a carrier mediated manner, use was made of the
non-penetrant thiol reagent mersalyl which can bind external mito-
chondrial thiols including those belonging to a variety of mitochondrial
carriers [see Ref. [29]]: no signiﬁcant inhibition of the initial rate of
swelling was found at mersalyl amount equal to 100 nmol/mg mito-
chondrial protein (Fig. 5b trace e), but at higher concentration
(300 nmol/mg mitochondrial protein) both the rate and the extent of
mitochondrial swelling in ammonium L-LAC were largely decreased;
Fig. 3. The occurrence and localization of L-LDH activity in Hep G2-M.Puriﬁed Hep G2-
M (0.01 mg protein) were incubated at 25 °C in 2 ml of PBS in the presence of rotenone
(2 μg) and either NADH (0.2 mM) or NAD+ (1 mM) and the absorbance (λ=334 nm)
was continuously monitored (for details see Section 2.6). At the time indicated by the
arrows the following additions were made: (trace a) pyruvate (0.1 mM), Triton X-100
(0.1%) and oxamate (5 mM); (trace b) Triton X-100 (0.1%), pyruvate (0.1 mM) and
oxamate (5 mM); and (trace c) L-lactate (1 mM) and oxamate (5 mM).The numbers
alongside the traces refer to the rate of NADH oxidation/NAD+ reduction calculated
as the tangent to the initial part of the progress curve and expressed as nmol NADH ox-
idized/NAD+ reduced×min−1×mg−1 mitochondrial protein.
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and extent of mitochondrial swelling in ammonium L-LAC, proved to re-
move largely mersalyl inhibition (Fig. 5b trace b).
3.4. Metabolism of L-lactate in Hep G2 cell mitochondria
In another set of experiments aimed at ascertaining the metabolic
fate of the imported L-LAC, the ability of externally added L-LAC to
cause oxygen uptake by isolated Hep G2-M (0.5 mg) was investigated
(Fig. 6a). We ﬁrst conﬁrmed the intactness of the mitochondria both
as described in Section 2.3 and by checking as a function of time the
constancy of the absorbance of NADH added to Hep G2-M. As expected
in the light of results in Fig. 5, PYR addition (1 mM) failed to cause oxy-
gen uptake. The addition of L-LAC (5 mM) to mitochondria caused oxy-
gen consumption at a rate of about 3 nmol O2×min−1×mg−1 protein.
Oxygen consumption was blocked by the addition of oxamate (5 mM),
but the further addition of succinate (5 mM) restored oxygen consump-
tion at a rate of 8 nmol O2×min−1×mg−1. When rotenone was addedinstead of oxamate only partial inhibition was found: the residual
rate of oxygen uptake was about 1 nmol O2×min−1×mg−1 protein,
this suggests the occurrence of the L-LAC oxidase [4]. In three sepa-
rate experiments the rates of L-LAC induced oxygen consumption
were 3.1±0.2 nmol O2×min−1×mg−1 protein. Surprisingly, addition
of either the uncoupler FCCP (1 μM)or 1 mMADPdid not stimulate res-
piration sustained by L-LAC (not shown). In parallel, the addition of glu-
tamate plus malate (5 mM each) caused oxygen consumption at a rate
of about 4±0.3 nmol O2×min−1×mg−1 protein; as a result of the ad-
dition of ADP (0.1 mM) the rate was 8±0.4 nmol O2×min−1×mg−1
protein. The addition of rotenone completely blocked oxygen consump-
tionwhichwas restored by further addition of L-LAC (5 mM)with a rate
of about 1 nmol O2×min−1×mg−1 protein. In another experiment
succinate oxidation (5 mM) was measured either in the absence or
presence of FCCP (1 μM) (not shown). The respiratory control ratios
(the ratio v+FCCP/v−FCCP, i.e. the ratio of the rate of oxygen consumption
in the presence or absence of the uncoupler FCCP), were about 2 in a
fairly good agreement with Refs. [19,46] in which poor mitochondrial
coupling was reported in Hep G2-M.
In the light of the above results and since the lack of stimulation by
ADP by L-LAC could be a result of the differences observed in a variety
of proteins contributing to the oxidative phosphorylation [see Ref.
[21]] as well as of the occurrence of the putative L-LAC oxidase [4], in
another experiment we checked whether L-LAC addition to isolated
Hep G2-M could generate an increase in membrane potential (ΔΨ) as
measured decrease of the safranine ﬂuorescence (Fig. 6b). No signiﬁcant
generation of membrane potential was found up to about 90 s after
L-LAC addition (5 mM) to Hep G2-M, when maximum ΔΨwas found
due to glutamate+malate (5 mM each) used as a control; after this
latency increase of mitochondrial membrane potential occurred at a
rate about 15% of that due to glutamate+malate. The generation of
membrane potential was completely prevented by both oxamate
(5 mM) and rotenone (2 μg). In all cases FCCP (1 μM) was found to
collapse ΔΨ; interestingly, no membrane potential generation was
found as a result of addition of PYR (1 mM); the further addition
of malate (2 mM) resulted in ΔΨ increase which did not differ signiﬁ-
cantly from that due to malate alone which caused ΔΨ generation at a
rate about 70% of that caused by glutamate+malate. This rate was
found to increase up 90% when L-LAC+malate were added (5 mM
each) (not shown).
In summary, the results in Figs. 5 and 6 show that externally added
L-LAC can enter both cells and mitochondria and conﬁrm that the
mitochondrial NAD-dependent L-LDH is located in the inner mitochon-
drial compartments. However the low rate of oxygen uptake and the
lateΔΨ generation suggest that L-LAC oxidation itself is onlymarginally
involved in energy production.
3.5. The reconstruction of the L-lactate/pyruvate shuttle and the efﬂux of
oxaloacetate, citrate and malate due to L-lactate addition to Hep G2 cell
homogenate
The above results pose the question as to the role of mitochondrial
L-LAC metabolism. Since cytosolic L-LAC oxidation arising from the ac-
tion of cytosolic L-LDH produces NADH plus H+, and since no increase
in cytosolic NADH level takes place after addition of L-LAC to Hep G2
cells in the absence of rotenone (not shown), we checked whether a
L-LAC/PYR shuttle [2,29,36,37,47] exists and can contribute to transfer
of reducing equivalents from the cytoplasm to mitochondria thus de-
creasing the acidity of the cytosol (Fig. 7a). To do this we tried to
reconstruct such a shuttle as in Ref. [47]: Hep G2 cell homogenate
(0.2 mg protein) was incubated with NADH, which was oxidized to a
small extent due to minimal mitochondrial rupture, and with L-LDH.
The concentration of PYR outside Hep G2-M was negligible, as shown
by the absence of absorbance change at 334 nm, which mirrors the
NADH concentration. As a result of the addition of L-LAC (5 mM) the ab-
sorbance decreased at a rate corresponding to 90 nmol NADH
Fig. 4. The dependence of L-LDH activity on increasing concentration of pyruvate, L-lactate, NADH and NAD+ in Hep G2-M solubilized with Triton X-100 and in the Hep G2 cytosolic
fractions.Experimental conditions were as in Fig. 3. Either puriﬁed solubilized Hep G2-M or Hep G2 cytosolic fractions (0.01 mg protein each) were incubated in 2 ml PBS and py-
ruvate (in the presence of 0.2 mM NADH), L-lactate (in the presence of 1 mM NAD+), NADH (in the presence of 0.2 and 0.8 mM pyruvate, in the case of mitochondria and cytosolic
fraction respectively), and 1 mM NAD+ (in the presence of 10 mM L-lactate) were added at the indicated concentrations to start the reactions. The rates of NADH oxidation/NAD+
reduction vo, measured as tangent to the initial part of the progress curve, are expressed as nmol NADH oxidized/NAD+ reduced×min−1×mg−1 protein.
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that L-LAC enters mitochondria via a putative L-LAC transporter and
then promotes the efﬂux of PYR newly synthesized insidemitochondria,
perhaps in a carrier mediated transport as in Ref. [37], thus constituting
a functional shuttle. Interestingly, α-CCN− (0.1 mM), which has been
shown to inhibit the uptake of both PYR and L-LAC by mitochondria
but with different sensitivities [47], and oxamate (5 mM) (not shown)
prevented the appearance of PYR.
In another series of experiments, since gluconeogenesis can occur in
Hep G2 cells [48], and since fatty acid/sterol synthesis occurs in tumor
growth, we checked whether, as a result of L-LAC uptake and metabo-
lism, OAA (the precursor of phosphoenolpyruvate), citrate (which in
the cytosol can both provide acetylCoA via the ATP dependent citrate
lyase and modulate glycolysis and fatty acid synthesis) and malate
(used to provide NADPH in the cytosol via the cytosolic malic enzyme)
could be exported outside the mitochondria. The appearance of OAA,
citrate and malate, outside mitochondria was monitored photometri-
cally by using speciﬁc metabolite detecting systems (see Section 2.11)
(Fig. 7b–d). Homogenates were found to oxidize externally added
NADH to a limited extent; the concentrations of OAA and malate
outside mitochondria were negligible since no change in the NADH
oxidation and NADP+ reduction was found as a result of the addition
of malate dehydrogenase and malic enzyme, the other components of
O.D.S. and M.D.S. respectively. As a result of addition of 5 mM L-LAC,
OAA (Fig. 7b), and malate (Fig. 7d) appearance outside mitochondria
was found as shown by the increase of the NADH oxidation rate in the
case of OAA and by the increase of the NADP+ reduction in the case of
malate.
To detect citrate appearance outside mitochondria (Fig. 7c),
homogenate previously added with the OAA detecting system was
added with CoA, ATP (1 mM each) and CL, this resulting in an in-
crease of the rate of NADH oxidation; the rate of citrate efﬂux wascalculated as 8 nmol×min−1×mg−1 protein by subtracting the
rate of OAA efﬂux previously measured (14 nmol×min−1×mg−1
protein), from the rate found after the addition of CoA, ATP and CL
which complete C.D.S. (22 nmol×min−1×mg−1 protein). Notice
that the initial rate of NADH oxidation (37 nmol×min−1×mg−1
protein) was due to the citrate already accumulated before CL addi-
tion. It should be noted that in all cases the metabolite efﬂuxes
depended on the mL-LDH reaction, as shown by inhibition oxamate
(not shown), in conditions under which the metabolite detecting
systems were not affected.
4. Discussion
As previously stated [49], “Many mysteries remain unsolved in our
understanding of even normal human metabolism, let alone that of
cancer cells”. This is certainly the case for metabolism of L-LAC, indeed
to quote Kennedy and Dewhirst [50] “The implications and conse-
quences of L-LAC utilization by tumors are currently unknown”. Thus
as part of an ongoing study on the mitochondrial L-LAC metabolism in
this paper we show that, as already found with both normal and cancer
cells [see Refs. [2,15,16]], a mitochondrial L-LDH exists in Hep G2 cells,
apparently different from the cytosolic isoform, and that it is located
in the inner compartment (Figs. 1–4). Accordingly, externally
added L-LAC can enter both Hep G2 cells and Hep G2-M (Figs. 5,6)
where it is metabolized to play an anaplerotic role, as shown by the
results of Fig. 7 where the L-LAC/PYR shuttle was reconstructed and
the capability of externally added L-LAC to cause the appearance of
OAA, malate and citrate outside mitochondria was ﬁrst shown in
cancer cells. These points will be discussed separately.
To assess the occurrence of the L-LDH in Hep G2-M, in addition to
the two experimental approaches already used in Ref. [15] and in the
light of previous papers by Hashimoto et al. [40,41], we have
Fig. 5. Externally added L-lactate can enter both Hep G2 cells and Hep G2 cell
mitochondria.a. Fluorimetric investigation of the redox state of the pyridine nucleo-
tides caused by L-LAC addition to Hep G2 intact cells.Hep G2 cells (0.5 mg cell protein),
were incubated at 25 °C in 2 ml PBS medium and reduction of pyridine nucleotides was
followed ﬂuorimetrically (λex=334 nm; λem=456 nm) as a function of time. At the
arrows the following additions were made: FCCP (1 μM), rotenone (2 μg), either L-lactate
(5 mM) or pyruvate (1 mM). In the inset Hep G2 cells incubated in PBS and treated with
1 mM FCCP (not shown)were added with rotenone (2 μg), glucose (10 mM) and ouabain
(100 μg) at time indicated by the arrows.b. Swelling in ammonium L-lactate solution of
Hep G2-M. Mitochondria (0.1 mg protein) were added to solution containing 0.25 M
sucrose (a), 0.1 M ammonium L-lactate addedwithmersalyl (300 nmol/mgmitochondrial
protein) (b) 0.1 M ammonium pyruvate (c), 0.1 M ammonium phosphate (d), 0.1 M
ammonium L-lactate added with mersalyl (100 nmol/mg mitochondrial protein) (e), and
0.1 M ammonium L-lactate (f). Where indicated 1mM cysteine was added. Mitochondrial
swelling was monitored at the wavelength of 546 nm as described in Section 2.8.
Fig. 6. Oxygen uptake (a) and membrane potential generation (b) by Hep G2-M added
with either L-lactate or other substrates.(a) Hep G2-M (0.5 mg protein) were incubated
in PBS medium (0.5 ml) at 25 °C and oxygen uptake was measured as a function of
time. At the arrows the following additions were made: L-lactate (5 mM), pyruvate
(1 mM), oxamate (5 mM), succinate (5 mM), rotenone (2 μg), malate (5 mM) plus glu-
tamate (5 mM), and ADP (0.1 mM). For details see the text.(b) Hep G2-M (0.5 mg pro-
tein) were incubated in 2 ml of PBS in the presence of 2.5 μM safranine and
ﬂuorescence (λex=520 nm, λem=570 nm) was monitored as a function of time. At
the arrow the following additions were made: malate (5 mM) plus glutamate
(5 mM), L-lactate (5 mM) either in the absence or presence of oxamate (5 mM) or ro-
tenone (2 μg), and pyruvate (1 mM).
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regard, we show co-localization of L-LDH with either mitochondrial
COX and MitoTracker Red; co-localization is speciﬁc since no L-LDH
co-localization occurs in Golgi and no mitochondrial co-localization
occurs for the cytosolic protein PAH [33]. Notice that a negligible
quantity of LDH does not co-localize with COX, this indicating that
LDH and COX co-localize inside mitochondria rather than in close
proximity. It should be noted that the L-LDH distribution in the mito-
chondrial compartments depends on the source of the mitochondria,
as shown in the landmark work of Brandt and Kline quoted in Ref. [2]
in which mL-LDH was not found completely inside mitochondria.
Nonetheless, in the present case we maintain that no L-LDH activity is
present in the mitochondrial intermembrane space since no L-LDH
activity is detectable before dissolving mitochondria. This also excludes
any cytosolic contamination, absence of which is also conﬁrmed by
the immunological analysis which shows that Hep G2-M containproteins recognized by both the L-LDH and COX-IV antibodies but
not by β-actin antibody. Finally the kinetic analysis carried out using
puriﬁed isolated mitochondria itself clearly shows that the L-LAC
activity is restricted to the inner mitochondrial compartments. Compari-
son made between cytosolic and mitochondrial LDH as based on the
kinetic studies suggests that the two L-LDHs differ from one another as
judged by the different afﬁnities for PYR, L-LAC and NAD+.
We also show that, as in other cancer cells [15,16], externally
added L-LAC can enter Hep G2 cells where it is metabolized with
reduction of the intracellular NAD(P)+ catalyzed by the mL-LDH
(Fig. 5a). The results in Fig. 5a by themselves cannot exclude the
possibility that NAD(P)H is generated inside mitochondria from PYR
newly synthesized in the cytosol via the cL-LDH and taken up by the
mitochondria. Against this, however, the lack of signiﬁcant inhibition
by arsenite, an inhibitor of the pyruvate dehydrogenase complex,
indicates that a minimal contribution to NAD(P)H formation is due
to PYR metabolism via pyruvate dehydrogenase. More importantly,
results in Figs. 5 and 6 show that, in distinction from L-LAC, PYR is
ineffective in causing a signiﬁcant mitochondrial swelling, oxygen
uptake or generation of membrane potential when added to Hep G2-M,
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to metabolize [13C1]-glucose mainly into L-LAC, alanine and glutamate,
and moreover incubation of cells with [13C3]pyruvate showed that the
label was mainly found in alanine, L-LAC and glutamate rather than in
acetylCoA [51]. The failure of PYR to act as an energy source for cancer
cells was shown as long ago as 1983 when a decreased activity of the
PYR translocator in tumor mitochondria was reported [52] and
conﬁrmed recently in PC3 prostate cells [15]. The reason for the reduced
mitochondrial metabolism of PYR must remain a matter of speculation
but one possibility is that the upregulation of cL-LDH results in increased
conversion of PYR to L-LAC at the expense of mitochondrial PYR utiliza-
tion. Accordingly L-LAC and PYR concentrations in hepatoma are about 3
and 0.03 mM respectively [53]. A direct role in shunting PYR away from
mitochondrial oxidation could also depend on the regulation of the
gene encoding the pyruvate dehydrogenase kinase 1 found in multiple
cell types [54]. Accordingly, mitochondrial function in tumor cells was
proposed to be expendable, resulting in a meager amount of PYR being
converted to acetyL-CoA throughmitochondrial pyruvate dehydrogenase
[55]; however other oxidizable substrates are actively used by tumor
mitochondria [56]. Whatever its origins may be, the failure of PYR to be
oxidized by mitochondria forces us to conclude that L-LAC itself is the
ﬁnal product of glycolysis in Hep G2 cells and that it is both released
from the cell and enters mitochondria. One could argue that conversion
of L-LAC to PYR in the mitochondrial matrix is, due to the reduced redox
state, energetically unlikely; however, the removal of the oxidationFig. 7. The reconstruction of the L-lactate/pyruvate shuttle and the efﬂux of oxaloacetate, cit
Hep G2 cell homogenates.Hep G2 cell homogenates (0.2 mg protein) were suspended at 25
the arrows the following additions were made: 1 e.u L-lactate dehydrogenase (LDH), L-lacta
0.1 mM α-cyanocinnamate (α-CCN−), 1 e.u malate dehydrogenase (MDH), CoA and ATP (1
oxidation/reduction was followed photometrically as a function of time at λ=334 nm. The
crease (d), measured as tangents to the initial part of the progress curves and expresse
Section 2.11.product by carrier mediated transport and mitochondrial metabolism
could overcome any thermodynamic difﬁculty.
We give a ﬁrst indication that L-LAC can enter mitochondria in a
carrier mediated manner (Fig. 5b). The point is that the thiol reagent
mersalyl, which cannot enter mitochondria, can inhibit Hep G2-M
swelling. Use of high mersalyl concentration merits some explanation.
Although mersalyl can inhibit the phosphate carrier with high sensitiv-
ity, when used at a low amount, mersalyl incubation longer than 1 min
withmitochondria is needed to begin to react additional mitochondrial
SH groups [57] which are about 100 nmol/mg protein [58]. Thus since
the swelling starts immediately after Hep G2-M addition to the ammo-
nium L-LAC solution, wewere forced to usemersalyl amounts so high as
300 nmol/mg mitochondrial protein. Accordingly mersalyl used at an
amount nmol/mg mitochondrial protein equal to 100 did not inhibit
the initial rate of swelling. Nonetheless given that the mersalyl inhibi-
tion is largely reversed by cysteine, we can rule out any additional effect
possibly resulting in mitochondria damage.
In the light of the results in Fig. 6 we assume that the contribution
of L-LAC to oxidative phosphorylation is negligible. It is tempting to
speculate that this might be due to L-LAC-dependent uncoupling
perhaps arising from activation of the mitochondrial uncoupling
protein as shown in Ref. [59] where accumulation of L-LAC occurred
with decrease of the mitochondrial membrane potential accompanied
by increased expression of uncoupling protein 2. This is consistent
with the reduced membrane potential generation due to L-LAC. In thisrate and malate in the extramitochondrial phase induced by the addition of L-lactate to
°C in 2 ml of PBS in the presence of either NADH (a–c) or NADP+ (d), (0.2 mM each). At
te (2.5 and 5 mM in a and b–d respectively), either in the absence or in the presence of
mM each), 1 e.u. citrate lyase (CL), and 0.2 e.u. malic enzyme (ME). Pyridine nucleotide
numbers along the traces are the rate of absorbance decrease (a–c) or absorbance in-
d as nmol NADH oxidized/NADP+ reduced×min−1×mg−1 protein. For details see
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about 90 s after L-LAC addition, when almost maximum ΔΨ generation
due to glutamate and malate is already obtained. On the other hand,
there is the possibility that a role might be played by the putative L-LAC
oxidase [4] whose existence is suggested by the initial experiment
(Fig. 6a) in which we found that a residual oxygen consumption occurs
in the presence of rotenone when L-LAC is used as a respiratory substrate
after glutamate and malate.
Fig. 6 raises the question as to whether and how mitochondrial
bioenergetics is modiﬁed in cancer and in particular in Hep G2 cells.
We show that, at least when L-LAC is used as respiratory substrates,
Hep G2-M are rather uncoupled i.e. can cause oxygen uptake without
any ADP stimulation. Accordingly L-LAC oxidation itself does not re-
sult in membrane potential generation; however since in the same
experiment glutamate plus malate can cause membrane potential
generation, but show a limited stimulation of oxygen uptake by ADP
we must conclude that in Hep G2-M the oxidative phosphorylation
is somehow impaired. Such a conclusion is not unique; accordingly
the oligomycin-insensitive oxygen consumption by Hep G2 cells
was found to be about 40% of the basal respiration [60]. Notice that
the oxidative phosphorylation system in Hep G2 cells proved to be
impaired even if less than that of JHH-6 cells; we agree that “At this
time, no real understanding of the biochemical basis for these observa-
tions exists, whichmay include the differences observed inmitochondrial
respiratory enzyme complexes, ATP synthase and IF1expression level and
regulatory function, as well as putative differences in ATP/ADP transport,
uncoupling proteins (UCPs) and membrane lipids” [21]. On the other
hand other events, including the transport of the respiratory substrates
into mitochondria in a carrier mediated manner and their oxidation,
might be responsible for the observed “uncoupling”. It should be also
noted that cancer mitochondria exhibit special properties, for instance
there is the possibility that external malate can be oxidized almost
exclusively via malic enzyme of the tumor mitochondria including Hep
G2-M [61,62]. This makes the explanation of the reported ﬁndings rather
puzzling and deserves a future detailed investigation.Scheme 1. L-Lactate metabolism in Hep G2 cells.Hep G2 cells have a basal rate of glycolysi
NAD+/NADH ratio. Pyruvate, which cannot enter mitochondria, is reduced to L-lactate.The
taken up from the blood, enters mitochondria via an unidentiﬁed carrier (1) inhibited by
acids obtained from either the environment or the degradation of cellular macromolecules,
by an L-LAC/PYR carrier (2), contributes to the oxidation of cytosolic NADH.Inside mitochon
acetyl-CoA), to OAA which can efﬂux from mitochondria perhaps via an L-LAC/OAA antipor
cytosolic malate dehydrogenase (cMDH), utilizing the low cytosolic NAD+/NADH ratio. Th
dentiﬁed carrier (4) into the cytosol where it can be converted to pyruvate by malic enzy
the mitochondria during citrate–malate antiport.As expected given that citrate is required
cells, citrate, newly synthesized in the matrix from OAA and acetylCoA, once exported to
(CL). The resulting acetyl-CoA is used by fatty acid synthase (FAS).The existence of themL-LDH and of the PYR efﬂux frommitochondria
is essential for the operation of the L-LAC/PYR shuttle (not previously
recognized in cancer cells) to occur (Fig. 7 panel a). Since in various
tumor lines the capacity for the re-oxidation of cytoplasmic NADH via
the malate aspartate shuttle approaches only 20% of the total respiratory
rate of the cell [63], the occurrence of other shuttle mechanisms is
required, one of which is the L-LAC/PYR shuttle. It is clear that speciﬁc
transport proteins must be present to allow for the operation of an intra-
cellular L-LAC shuttle by which L-LAC is imported into the mitochondria
and newly synthesized PYR is exported into the extramitochondrial
phase. In this regard we have already shown that the carriers which
mediate L-LAC transport in rat heart [47] and, more importantly, in
liver mitochondria [37] are separate from the carrier which catalyzes
PYR transport; in particular the mitochondrial pyruvate carrier (MPC
in the terms of Halestrap), proved to differ from the monocarboxylate
transporters (MCTs) [64], and hence we might speculate that MCT1 is
one of the mitochondrial L-LAC transporters. Interestingly, in initial
experiment we have found that the L-LAC/PYR shuttle is inhibited
by phenylsuccinate which in rat [37] and pig liver mitochondria
(unpublished results) can impair the L-LAC carriers, but not the
PYR carrier. Since phenylsuccinate can inhibit a variety of carriers,
including the dicarboxylate carrier [see Ref. [29]], further work is
required to elucidate the mechanism of L-LAC-dependent mitochon-
drial trafﬁc in Hep G2 cells.
The results described here together with those of Refs. [15,16]
necessitate a complete revision of our thinking about L-LAC energy
metabolism in cancer cells. In addition to/distinction with views com-
monly held (see Introduction section) we propose (see Scheme 1)
that L-LAC, in addition to being produced internally, can also enter the
cell and be imported into the mitochondria, where it is metabolized
by the mL-LDH. This metabolism plays an anaplerotic role.
Clearly the identiﬁcation of the carrier/s involved in the metabolite
trafﬁc of Hep G2-M needs further investigation as do other aspects of
this novel metabolic activity. A major spur for such investigations is
that knowledge of the details of L-LAC metabolism in cancer cellss, converting glucose to pyruvate and generating ATP with a decrease of the cytosolic
newly synthesized L-lactate either is exported from the cell or, together with L-lactate
the thiol reagent mersalyl.In addition to other substrates like amino acids and fatty
Hep G2-M can oxidize L-lactate via the novel mL-LDH. The L-LAC/PYR shuttle, promoted
dria pyruvate is then converted, probably via pyruvate carboxylate (PC) (activated by
ter (3); in the cytosol OAA can start gluconeogenesis and/or be converted to malate by
e malate, newly synthesized in the mitochondria, in turn, can be exported via an uni-
me (ME), generating NADPH to be used in fatty acid synthesis, and/or be returned to
for the synthesis of fatty acids/sterols used to generate lipid membranes for daughter
the cytosol perhaps by the tricarboxylate carrier (5), is cleaved by ATP citrate lyase
1689R. Pizzuto et al. / Biochimica et Biophysica Acta 1817 (2012) 1679–1690might be used to design novel drugs/therapies as new metabolic
targeting strategies to selectively debilitate tumors [65,66].
Thus, 60 years after Dianzani's paper which, to the best of our
knowledge, was the ﬁrst indication of the ability of liver mitochondria
to oxidize L-LAC [67], and 40 years after the demonstration via histo-
chemistry of the existence of the L-LDH inside mitochondria [68], the
occurrence of L-LAC metabolism inside mitochondria catalyzed by an
mL-LDH is conﬁrmed in liver cancer cells.
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